Nolato NOLA B

Stockholm | Industrials | Polymer-based contract manufacturing (medtech and industrial)
Follow Nolato free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Updated: 18 Sep 2026 Base analysis: 6 Apr 2026

The news check keeps the assessment current.

General analysis — not personal advice.

NEUTRAL Partly clear

Hold off on adding until the company demonstrates a steadier margin trend and clearer pricing impact; an existing position can be maintained if you accept higher near-term earnings risk.

Q2 showed continued margin pressure from raw-material costs and delayed price pass-through, requiring the case to be reassessed until a more stable margin trend becomes visible.

Market sentiment Negative →
Trend: Stable

Sentiment remains subdued after Q2 but the M&A announcement has provided some relief as it demonstrates continued growth ambition without straining the balance sheet.

Risk assessment Medium
Dilution: Low Positive cash flow; no announced equity raise
Jurisdiction: Low Mainly Sweden/EU/US; limited high-risk exposure
Execution: Medium New factory ramps require validation and quality control

NEUTRAL is the call. Negative is the market mood. Medium risk means some things can go wrong.

Latest change
  • 18 Jul 2026 — Q2 showed FX-adjusted revenue growth but pressured profitability from higher raw material/oil costs and delayed price pass-through, triggering a sharp negative share reaction.

The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.

Show all changes (5) — follow the company free
About the company

Nolato is a contract manufacturer developing and producing polymer-based components and systems (plastics, silicone, TPE) for medical/drug delivery and industrial customers. The company is profitable and in a mature phase, focusing on margin improvement and capacity expansion. A key growth driver is scaling pen/autoinjector components linked to diabetes and obesity therapies.

Sector: Polymer-based contract manufacturing (medtech and industrial)
Type: Industrial
Next report (Q3)
29 Oct 2026
Catalysts
●
29 Oct 2026
Q3 2026 interim report High
○
Q4 2026
Completion of Romania divestment Medium
◦
Date TBA
Consolidation of M&M Qualtech
Bull case

Resumed M&A activity and volume ramp from the Hungary project can strengthen the growth profile once margins stabilise.

Bear case

Persistent margin pressure from raw materials and delayed price compensation risks keeping profitability low and triggering negative estimate revisions.

Why this signal

Q2 showed continued margin pressure from raw-material costs and delayed price pass-through, requiring the case to be reassessed until a more stable margin trend becomes visible.

Recent news
  • Nolato has signed an agreement to acquire Irish electronics company M&M Qualtech with around 200 employees and expected 2026 revenue of SEK 385 m. The deal is financed with own cash and existing credit facilities with no new share issue. Operations will be consolidated from September 2026 and renamed Nolato Qualtech. Affärsvärlden reiterated its buy recommendation after the announcement.

Key figures

Revenue
Q2 2026
SEK 2.5B
EBITDA
Q2 2026
SEK 0.4B
Net income
Q2 2026
SEK 169M
Cash
Q2 2026
SEK 287M
Total debt
Q2 2026
SEK 1.1B
Shares outstanding
Q2 2026
SEK 269M
EPS
Q2 2026
SEK 0.63
Exchange
Stockholm
Type
Industrials
Sector
Polymer-based contract manufacturing (medtech and industrial)
Nolato NOLA B
Nolato — this picture changes. Follow free
Follow Nolato free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.